Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest news about Teva API aggregated by PharmaCompass.com.

    Client Virtual Booth

    TEVA API

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Teva API
    Israel Flag
    Country
    Country
    Israel
    Address
    Address
    124 Devorah Haneviaa St.Tel Aviv 6944020, Israel
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.teva-api.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/teva-active-pharmaceutical-ingredients/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Teva weighs potential sale of its $2B API business
    Teva weighs potential sale of its $2B API business

    https://www.fiercepharma.com/pharma/teva-weighs-sale-2b-drug-ingredients-business-new-ceo-francis-embarks-pivot-growth-strategy

    Fraiser Kansteiner FIERCE PHARMA
    07 Jul 2023
    Share Share
    Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
    Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

    https://investors.alvotech.com/news-releases/news-release-details/alvotech-and-teva-announce-acceptance-us-biologics-license

    PRESS RELEASE
    06 Jan 2023
    Share Share
    Teva, Allergan poised to put their opioid lawsuits to bed
    Teva, Allergan poised to put their opioid lawsuits to bed

    https://www.fiercepharma.com/pharma/teva-abbvies-allergan-lock-66-billion-settle-thousands-us-opioid-lawsuits

    Fraiser Kansteiner FIERCEPHARMA
    23 Nov 2022
    Share Share
    Teva Pharma Appoints Novartis, Biogen Vet as New President and CEO
    Teva Pharma Appoints Novartis, Biogen Vet as New President and CEO

    https://www.biospace.com/article/teva-pharma-appoints-new-president-and-ceo/

    Mark Terry BIOSPACE
    22 Nov 2022
    Share Share
    Teva Finalizes Nationwide Opioid Settlement Terms
    Teva Finalizes Nationwide Opioid Settlement Terms

    https://www.businesswire.com/news/home/20221121005916/en

    BUSINESSWIRE
    22 Nov 2022
    Share Share
    Teva Announces Unique Collab with HealthSnap of its Respiratory Digital Health
    Teva Announces Unique Collab with HealthSnap of its Respiratory Digital Health

    https://www.tevapharm.com/news-and-media/latest-news/teva-announces-unique-collaboration-with-healthsnap-to-expand-the-reach-of-its-respiratory-digital-health/

    TEVAPHARM
    14 Nov 2022
    Share Share
    Teva Announces Collabo with Rimidi to Expand Reach Respiratory Digital Health
    Teva Announces Collabo with Rimidi to Expand Reach Respiratory Digital Health

    https://www.businesswire.com/news/home/20221114005344/en/Teva-Announces-Unique-Collaboration-with-HealthSnap-to-Expand-the-Reach-of-its-Respiratory-Digital-Health-Platform

    BUSINESSWIRE
    14 Nov 2022
    Share Share
    Teva's Generic Penciclovir Receives Approval in the U.S.
    Teva's Generic Penciclovir Receives Approval in the U.S.

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212710

    FDA
    09 Nov 2022
    Share Share
    Teva refiles long-acting schizophrenia drug after FDA rejection
    Teva refiles long-acting schizophrenia drug after FDA rejection

    https://www.fiercepharma.com/pharma/take-2-teva-refiles-approval-long-acting-schizophrenia-drug-months-after-fda-rejection

    Nick Paul Taylor FIERCEPHARMA
    08 Nov 2022
    Share Share
    Teva to Present Research from CONNECT1 and CONNECT2 Trials at ACAAI
    Teva to Present Research from CONNECT1 and CONNECT2 Trials at ACAAI

    https://www.businesswire.com/news/home/20221107005119/en

    BUSINESSWIRE
    07 Nov 2022
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search